connexT

Innovation for Regeneration

(주) 코넥스트

Introduction to Connext

2019-12

connext

Innovation for Regeneration

Disclaimer

Please note that the forecasting information contained in this document is based on our market forecast and business plan, so it is subject to change depending on business and market conditions.

The contents of this document may not be provided, distributed, transmitted or used in whole or in part directly or indirectly to third parties for any purposes without the prior written consent of the company.

0 0 Company Overview

connext
Innovation for Regeneration

1. Company name: Connext Co., Ltd.
2. Established date: October 25th, 2017
3. Capital: KRW 289,414,000 (Face value per share: KRW 500, Number of stocks: 578,828)
4. Address: Suite 1707, West Wing, 322 Teheran-ro Gangnam-gu, Seoul, 06211, Republic of Korea (in KITECH bmtc building)
5. Employee: 8 (R&D manpower: 5)
6. Field of business
   - Development, production and sales of biological products
   - R&D services such as biological products
   - Manufacturing of research and therapeutic cell
   - Manufacture and sales of raw materials and subsidiary materials for biological processes
   - Manufacture and sales of drug delivery device
   - Development, production and sales of surgical medical devices
   - R&D service business for surgical medical devices
   - Manufacture and sales of medical device parts
   - Other incidental projects and investments related to each of above
   - All subsidiary businesses related to each of above

0 0 History

connexT
Innovation for Regeneration

- JUN 2014 Started the development of TLR5 agonist-based radiation exposure treatment
- JAN 2016 Commenced the development of production technology for musculoskeletal customized biological tissue regeneration system
- **OCT 2017 Corporation established (Spin-off from KITECH, where positions of founders are maintained)**
- JAN 2018 IND (Investigational New Drug Drug) for TLR5 agonist approved and Phase 1 clinical trial commenced
- APR 2018 Selected as a growth support project for investment-linked public technology commercialization company, funded by Ministry of Science and ICT
- JUN 2018 Established R&D partnership with the Catholic University of Korea Seoul St. Mary's Hospital
- AUG 2018 Selected as company supported by *R-TECH Project* funded by Korea Technology Finance Corporation
- AUG 2018 Certified as Venture Business
- FEB 2019 Certified as Corporate Research Institute
- APR 2019 Selected as a company supported by SME New Substance Development Support Project (Korea Institute of Toxicology, Pre-clinical)
- MAY 2019 Selected as a company participating in *IP-R&D Strategic Support Project* (Korea Intellectual Property Strategy Agency)
- OCT 2019 Series A closed


CEO
SAB
Technology
CTO
Quality
CQO
Communication
CCO
Operation
COO
R&D
Pre-clinical / Clinical
Research TDzyme Mfg.
GMP Mfg.
IND
IP Management
IR
Communication Channel
Licensing Deal
TDzyme Marketing
Financing
Accounting
Human Resource
TDzyme Operation

connexT
Innovation for Regeneration

Woo-Jong Lee (Founder & CEO)

- Seoul National University, BS, MS, and Ph.D. in Food Engineering
- Major projects
  - Development of TLR5 agonist-based radiation exposure treatment
  - Medical mold R&BD project Development of production technology for biological tissue regeneration system customized for musculoskeletal system (Sub-project manager, Total funding KRW 2.6 billion)
  - Establishment of KBCC (Korea Biotechnology Commercialization Center) project (Participating researcher, Establishment of CMO for cGMP biopharmaceutical)

Chi-Min Choi (Co-founder)

- Seoul National University, BS in Food Engineering
- Seoul National University, MS in Agricultural Biotechnology Cooperative Course
- Major projects
  - Development of GMP manufacture process for various biopharmaceuticals and vaccine drug substance
  - Scale-up and licensing-out of developed technologies and items

0 0 R&D Infrastructure

connexT
Innovation for Regeneration

connexT
Innovation for Regeneration

KITECH spin-off entitled to utilize R&D equipment in KITECH

Biopharmaceutical

Biopharma infrastructure

- Freedom EVO TeChrom (Tecan) and more
- 47 kinds / KRW 1.55 billion

Medical Device

Interventional medical device infrastructure

- Medical injection / extrusion equipment
  * Injection: 55/160 ton, insert, two-shot
  * Extrusion: for precision tube with 0.3 ~3 mm, 4 lume
- Post-processing equipment for catheter manufacture
- Precision measurement equipment (3D CT scanner, C
- Cleanroom facility (Class 100,000 grade, 3 rooms)
- 5MeV grade E-beam facility

Overview of Pipelines

connexT
Innovation for Regeneration

Technology	Indication
TLR5 agonist (**First-in-Class**)	Mucositis
	GvHD (Graft-versus-host disease)
	ARS (Acute Radiation Syndrome)
Collagenase (**Best-in-Class**)	Cellulite
	Removal of necrotic tissue such as diabetic foot ulcer (Wound debridement)

- **Pipelines enabled by transferred technologies developed through large R&D projects funded by Korean government**
  - ✓ Development of TLR5 agonist-based radiation exposure treatment (Principal Investigator, Total fund: **KRW 8 billion**, June 2013 ~ August 2019)
  - ✓ Development of production technology for biological tissue regeneration system customized for musculoskeletal system(Sub-project Investigator, Total fund: **KRW 2.6 billion**, January 2016 ~ December 2019)
- **Phase 1 clinical trials in progress,** and **focusing on translational research to expand indications**

Pipeline

Portfolio	Indication		Pre-clinical	Phase 1
TLR5 agonist (**First-in-Class**)	**CNT101**	**Mucositis**	→	
	CNT102	GvHD	→	
	CNT103	ARS	→	
Collagenase (**Best-in-Class**)	**CNT201**	**Cellulite**	→	
	CNT202	Removal of necrotic tissue (Wound debridement)	→	


코넥스트
한국생산기술연구원
에이피테크놀로지
전문 CMO
(IntegrityBio/
바이넥스)
오송첨단의료산업
진흥재단
CMC
서울성모병원
안전성평가연구소
한국원자력의학원
전문 CRO
(Biomodels 등)
비임상
삼성서울병원
전문 CRO
(메디팁/KCRN 등)
IND 및 임상

감 사 합 니 다.